PEPTIDE BIOLOGY
GHRH ANALOG
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a physiological signal involved in regulating growth hormone secretion from the pituitary gland.
PEPTIDE PERFORMANCE RESEARCH LIBRARY
TESAMORELIN RESEARCH.
An educational overview of a growth hormone-releasing hormone analog studied extensively in endocrine and metabolic research, including human clinical investigation of visceral adipose tissue in HIV-associated lipodystrophy.
RESEARCH OVERVIEW
WHAT IS TESAMORELIN?
ENDOCRINE SIGNALING
GH / IGF-1 AXIS
GHRH receptor signaling stimulates endogenous growth hormone release, which can subsequently influence insulin-like growth factor 1 and other downstream endocrine pathways.
HUMAN EVIDENCE
CLINICAL RESEARCH
Tesamorelin has been evaluated in multiple randomized controlled human studies, giving it a substantially larger clinical evidence base than many experimental peptides.
MECHANISMS UNDER INVESTIGATION
GHRH, GROWTH HORMONE & IGF-1.
Tesamorelin works through the body's growth hormone-releasing hormone pathway rather than functioning as growth hormone itself.
RECEPTOR SIGNALING
PITUITARY RESPONSE
GHRH receptor activation stimulates pituitary somatotroph cells involved in endogenous growth hormone secretion.
ENDOCRINE SIGNAL
GROWTH HORMONE
Growth hormone participates in metabolic and endocrine pathways involving lipid metabolism, body composition, tissue signaling, and IGF-1 production.
DOWNSTREAM SIGNALING
IGF-1
Clinical studies of tesamorelin have demonstrated increases in circulating IGF-1, consistent with activation of the physiological GH/IGF-1 axis.
HUMAN CLINICAL EVIDENCE
VISCERAL ADIPOSE TISSUE RESEARCH.
Large randomized studies have evaluated tesamorelin in adults with HIV-associated excess abdominal visceral adipose tissue.
PHASE 3 RESEARCH
VISCERAL FAT
Two multicenter Phase 3 trials enrolled more than 800 antiretroviral-treated adults with HIV and excess abdominal fat. Researchers observed significant reductions in visceral adipose tissue compared with placebo.
LONGER-TERM STUDY
52-WEEK DATA
Extension studies found that reductions in visceral adipose tissue could be maintained during continued treatment, while visceral fat tended to return after discontinuation.
ADDITIONAL RESEARCH
LIVER FAT
A smaller randomized clinical study also investigated hepatic fat and reported reductions in liver fat alongside reductions in visceral adipose tissue.
IMPORTANT CONTEXT
APPROVED USE IS SPECIFIC.
Tesamorelin has an FDA-approved prescription indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
That indication should not be generalized to unrelated populations or purposes. The FDA labeling specifically states that tesamorelin is not indicated for weight-loss management.
RESEARCH LIMITATIONS
WHAT THE DATA DOESN'T ESTABLISH.
POPULATION
SPECIFIC STUDY GROUPS
Strong evidence in HIV-associated lipodystrophy cannot automatically establish equivalent effects in healthy individuals or unrelated populations.
BODY WEIGHT
NOT GENERAL WEIGHT LOSS
Reduction of visceral adipose tissue in a defined clinical population is different from establishing a therapy for general weight management.
LONG-TERM QUESTIONS
ONGOING CONTEXT
Long-term cardiovascular effects and outcomes outside the studied clinical indication require careful interpretation and continued research.
RESEARCH SOURCES
PUBLISHED REFERENCES.
Phase 3 Clinical Research
Falutz J, Mamputu JC, Potvin D, et al.
Effects of tesamorelin, a growth hormone-releasing factor,
in HIV-infected patients with abdominal fat accumulation.
Pooled Phase 3 Analysis
Two multicenter randomized controlled studies evaluated
visceral adipose tissue outcomes in more than 800 adults
with HIV-associated abdominal fat accumulation.
Visceral & Liver Fat Research
Stanley TL, Feldpausch MN, Oh J, et al.
Effect of tesamorelin on visceral fat and liver fat in
HIV-infected patients with abdominal fat accumulation.
JAMA. 2014.
Regulatory Information
U.S. Food and Drug Administration prescribing information
for tesamorelin-containing prescription products.
EDUCATIONAL RESEARCH NOTICE
Information presented in the Peptide Performance Research Library is provided for general educational and scientific reference purposes only.
This content is not medical advice, diagnosis, treatment guidance, dosing information, or personal-use instruction. Research findings and regulatory information should be interpreted according to the populations and conditions actually studied.